$FOCL

Schulz Fran purchased $48K of FOCL

Schulz Fran purchased 10,000 shares of EDAP TMS SA (FOCL) at $4.75 on 2026-08-14.

Original reporting
SEC EDGAR · Schulz Fran
Published Aug 17, 2026, 10:04 AM UTC
Analysis
alphai AI DeskAI-generated
Added to alphai Aug 17, 2026, 10:18 AM UTC. Informational, not investment advice.
How this was made
alphai summarizes source reporting and applies a structured AI analysis for relevance, timing, sentiment and ticker impact. Always verify material claims with the original publisher.
alphai market briefInsider activity
Primary signal
$FOCL
Bullish
low confidence
Mentioned
$FOCL
Relevance
4/10
alphai data visualization · based on SEC EDGAR
Decision brief

The 30-second read

$FOCLBullishLow
01

Why it matters

A director’s open-market purchase is a sentiment input, but without any accompanying corporate event (earnings, guidance, trial results, contracts), it is unlikely to drive a sustained repricing.

02

Market read

Traders may note the insider buy as a small positive signal, but the disclosure alone is not a high-conviction catalyst.

03

What to watch

The filing states no pre-arranged 10b5-1 plan, but it still does not explain motivation, timing constraints, or whether other insiders are buying/selling.

Relevance 4/10Novelty 3/10Timing: filed 2026-08-17, transaction dated 2026-08-14

Background

The article is an SEC Form 4 insider transaction disclosure for EDAP TMS SA (FOCL).

Company-level read

Ticker impact

$FOCLBullishLow confidence
Context

EDGAR Form 4 shows director Schulz Fran bought 10,000 shares of FOCL at $4.75 on 2026-08-14, totaling $47,500.

Expected impact

Likely limited near-term impact; any effect is sentiment-driven and typically small versus earnings or guidance.

Evidence & confidence

Form 4 insider buys are primary-source but the transaction size and lack of accompanying company news usually do not reset valuation or near-term expectations.

Market effects

No sector-wide signal; this is company-specific insider activity only.

None indicated.

None indicated.

Counterpoint

Insider buys can be routine, planned, or tax/money-management related, and this filing provides no new operational or financial information.

Key entities

  • EDAP TMS SA

    Company whose shares (FOCL) are subject of the Form 4 insider transaction.

  • Schulz Fran

    Director who purchased 10,000 shares at $4.75 on 2026-08-14.

Full insider trading history

This story covers one filing. See everything behind it: every insider buy and sell on record, 10b5-1 plans, late filings, and which officers and directors are trading.

Related articles

$FOCLMedAI 8/10

FocalTherics (FOCL) Q2 2026 Earnings Call Transcript

FocalTherics (FOCL) reported Q2 2026 earnings with $13.2M in HIFU revenue, up 39% YoY. They sold 13 Focal One systems, a 44% increase. The company expanded its footprint in the U.S. and internationally, including sales to Cleveland Clinic and Kaiser Permanente. They submitted a 510(k) application for FocalConnect and expect CMS reimbursement increases. The company is also expanding into new indications like BPH and endometriosis, targeting a $10B revenue opportunity.

$FOCLMed

FocalTherics Q2 Earnings Call Highlights

FocalTherics (NASDAQ:FOCL) reported Q2 highlights from its earnings call. U.S. Focal One procedure volumes rose 47% YoY. HIFU gross margin increased to 55.6% from 51.1%. Cash was $21.5M and it drew about €14M under its EIB credit facility. The company plans a $40M Aug. 14 offering and reiterated 2026 HIFU revenue guidance of $50M to $54M.

$FOCLMedAI 8/10

FocalTherics Reports Q2 2026 Revenue of $13.2M; Net Loss $14.5M

FocalTherics (FOCL) reported Q2 2026 continuing-operations revenue of $13.2M, up 39% year over year, with gross profit of $7.3M and 55.6% gross margin. Net loss was $14.5M, or $0.39 per share. Cash was $21.5M at June 30, 2026. The company also announced an underwritten public offering for about $40M expected to close Aug. 14, 2026.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Second Quarter 2026 Financial Results 39% Revenue Increase and 47% Growth in U.S. Procedures AUSTIN, Texas, August 13, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced financial resul

$FOCLMed

FocalTherics Reports Preliminary Q2 2026 Results, Announces $40 Million Offering; Stock Down

FocalTherics (FOCL) reported preliminary unaudited Q2 2026 results. Revenue is expected at $12.7 to $13.2 million, up 34% to 39% from $9.7 million in Q2 2025, with gross margin at 54% to 56% versus 42.5%. Cash and investments were $21.5 million as of June 30. The company priced a public offering of 8.425M ADS at $4.75 to raise about $40M gross, with an option for 1.26375M more ADS.

$FOCLMed

EDAP TMS SA (FOCL): Results of Operations and Financial Condition

EDAP TMS SA (FOCL) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99.1 FocalTherics™ Reports Preliminary Financial Results for Second Quarter of 2026 AUSTIN, Texas, August 11, 2026 - FocalTherics™ (Nasdaq: FOCL) (the “Company”), a global leader in robotic focal therapy, today announced preliminary unaudited financial results for the Com